Table 2.
Meta-analysis results of adverse drug reactions (ADRs).
| Outcomes | Trials | Experimental group (Events/Total) | Control group (Events/Total) | SM | RR, 95%CI | I2 | P |
|---|---|---|---|---|---|---|---|
| Neutropenia | 20 | 269/698 | 416/696 | REM | 0.65 [0.54, 0.79] | 79% | <0.00001 |
| Anemia | 13 | 135/379 | 195/375 | REM | 0.68 [0.52, 0.89] | 70% | 0.005 |
| Thrombocytopenia | 20 | 155/602 | 237/595 | REM | 0.65 [0.51, 0.82] | 62% | 0.0004 |
| Nausea and vomiting | 19 | 263/647 | 377/646 | REM | 0.73 [0.64, 0.82] | 32% | <0.00001 |
| Diarrhea | 10 | 62/307 | 111/301 | REM | 0.58 [0.45, 0.75] | 0% | <0.0001 |
| Hepatic dysfunction | 14 | 45/442 | 86/446 | REM | 0.55 [0.40, 0.77] | 0% | 0.0005 |
| Renal dysfunction | 10 | 14/324 | 34/323 | REM | 0.48 [0.26, 0.88] | 0% | 0.02 |
| Neurotoxicity | 12 | 123/389 | 162/379 | REM | 0.78 [0.65, 0.92] | 0% | 0.004 |
| Alopecia | 4 | 50/145 | 61/138 | REM | 0.77 [0.61, 0.97] | 0% | 0.03 |
| Stomatitis | 6 | 45/174 | 62/174 | REM | 0.73 [0.53, 1.00] | 0% | 0.05 |
RR, risk ratio; CI, confidence interval; SM, statistical method; REM, random-effect model.